{"product_id":"coherus-five-forces-analysis","title":"Coherus Biosciences Porter's Five Forces Analysis","description":"\u003cdiv class=\"product-includes\"\u003e\n \u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n \u003cdiv class=\"product-box-includes\"\u003e\n \u003cdiv class=\"title-row-includes\"\u003e\n \u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n \u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"content-row-includes\"\u003e\n \u003cp\u003eAnalyzes Coherus Biosciences' competitive environment, examining the five forces impacting its market position.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"plus-icon\"\u003e\n \u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n \u003cdiv class=\"product-box-includes\"\u003e\n \u003cdiv class=\"title-row-includes\"\u003e\n \u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n \u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"content-row-includes\"\u003e\n \u003cp\u003eSwap in your own data, labels, and notes to reflect current business conditions.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\u003cdiv class=\"container_new_design\"\u003e\n \u003cdiv class=\"text-section text-1_new_design\"\u003e\n \u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eCoherus Biosciences Porter's Five Forces Analysis\u003c\/h2\u003e\n \u003cp\u003eThis preview is the full Coherus Biosciences Porter's Five Forces analysis you'll download. It assesses industry rivalry, supplier power, buyer power, threats of substitutes, and threats of new entrants. You will receive the complete, unedited document immediately after purchase. No modifications are needed; it's ready to use.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"image-section image-1_new_design\"\u003e\n \u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n \u003ch2\u003ePorter's Five Forces Analysis Template\u003c\/h2\u003e\n \u003csection class=\"pr-shrt-dscr-box\"\u003e\n \u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n \u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n \u003ch3\u003eFrom Overview to Strategy Blueprint\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n \u003cp\u003eCoherus Biosciences faces moderate rivalry, influenced by competition in biosimilars. Supplier power is moderate, dependent on biologics manufacturers. Buyer power is also moderate, with payers impacting pricing. The threat of new entrants is moderate, given regulatory hurdles and R\u0026amp;D costs. Substitute products pose a low threat currently.\u003c\/p\u003e\n \u003cp\u003eThe complete report reveals the real forces shaping Coherus Biosciences’s industry—from supplier influence to threat of new entrants. Gain actionable insights to drive smarter decision-making.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\u003cdiv class=\"container_new_design\"\u003e\n \u003cdiv class=\"text-section text-1_new_design\"\u003e\n \u003cdiv class=\"frst_big_letter_heading\"\u003e\n \u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n \u003csection class=\"sub-highlight-box\"\u003e\n \u003cdiv class=\"sub-highlight-icon\"\u003e\n \u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n \u003ch3\u003eLimited Supplier Concentration\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"sub-highlight-content\"\u003e\n \u003cp\u003eCoherus Biosciences depends on third-party manufacturers for its products. The supplier base, although potentially limited for specific components, isn't overly concentrated. This situation offers Coherus some bargaining power. In 2024, Coherus has contracts with multiple manufacturing partners. This strategy helps to mitigate risks.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n \u003csection class=\"sub-highlight-box\"\u003e\n \u003cdiv class=\"sub-highlight-icon\"\u003e\n \u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n \u003ch3\u003eStandardized Manufacturing Processes\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"sub-highlight-content\"\u003e\n \u003cp\u003eBiosimilar manufacturing relies on standardized processes, diminishing the need for unique supplier inputs. This standardization gives Coherus flexibility to change suppliers, lessening the impact of any single supplier's power. In 2024, the biosimilars market grew, but supplier bargaining remained moderate due to process commonality. Coherus can negotiate better terms because of this standardization, as seen with its cost-saving strategies in 2024. \u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"image-section image-1_new_design\"\u003e\n \u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003csection class=\"highlight-box\"\u003e\n \u003cdiv class=\"highlight-icon\"\u003e\n \u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n \u003ch3\u003eContractual Agreements in Place\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"highlight-content\"\u003e\n \u003cp\u003eCoherus Biosciences probably uses long-term contracts with main suppliers, ensuring price stability and a reliable supply chain. These contracts limit suppliers' ability to raise prices or alter terms. In 2024, such agreements are increasingly vital in the biotech sector, given supply chain volatility. For instance, many biosimilar manufacturers negotiate multi-year deals. This approach is critical to manage cost and risk effectively.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n \u003cdiv class=\"product-green-section\"\u003e\n \u003cdiv class=\"product-box-green-section4\"\u003e\n \u003cdiv class=\"title-row-green-section\"\u003e\n \u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n \u003ch3\u003eBiosimilar Market Competition\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"content-row-green-section blur_box\"\u003e\n \u003cp\u003eThe biosimilar market's competitiveness curtails supplier bargaining power. Suppliers must offer competitive prices to win contracts with companies such as Coherus. This dynamic benefits biosimilar makers by keeping input costs in check. Lower input costs can improve profitability. \u003c\/p\u003e\n \u003cul class=\"lst_crct\"\u003e\n \u003cli\u003e\u003cstrong\u003eCompetition among suppliers, such as those providing raw materials or manufacturing services, is intense.\u003c\/strong\u003e\u003c\/li\u003e\n \u003cli\u003e\u003cstrong\u003eBiosimilar manufacturers can switch suppliers if they don't offer competitive terms.\u003c\/strong\u003e\u003c\/li\u003e\n \u003cli\u003e\u003cstrong\u003eCoherus's ability to negotiate favorable terms is enhanced by a wide choice of suppliers.\u003c\/strong\u003e\u003c\/li\u003e\n \u003cli\u003e\u003cstrong\u003eThe market's growth, projected to reach billions by 2028, intensifies this pressure.\u003c\/strong\u003e\u003c\/li\u003e\n \u003c\/ul\u003e\n \u003c\/div\u003e\n \u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"product-box-green-section4\"\u003e\n \u003cdiv class=\"title-row-green-section\"\u003e\n \u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n \u003ch3\u003ePotential for Internal Manufacturing\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"content-row-green-section blur_box\"\u003e\n \u003cp\u003eCoherus Biosciences currently relies on outsourcing for its manufacturing needs, but there's a strategic possibility for internal production. This potential shift to insourcing gives Coherus leverage, as it reduces dependency on external suppliers. Having the option to manufacture internally limits the suppliers' ability to dictate terms or raise prices. The company's strategic flexibility is enhanced by this potential, impacting supplier bargaining power.\u003c\/p\u003e\n \u003cul class=\"lst_crct\"\u003e\n \u003cli\u003e\u003cstrong\u003e2024: Coherus's commitment to biosimilar development and potential for in-house manufacturing.\u003c\/strong\u003e\u003c\/li\u003e\n \u003cli\u003e\u003cstrong\u003eThe company's financial strategy includes evaluating manufacturing options.\u003c\/strong\u003e\u003c\/li\u003e\n \u003cli\u003e\u003cstrong\u003eThis approach potentially offers cost control and supply chain resilience.\u003c\/strong\u003e\u003c\/li\u003e\n \u003cli\u003e\u003cstrong\u003eCoherus's strategic planning considers long-term manufacturing capabilities.\u003c\/strong\u003e\u003c\/li\u003e\n \u003c\/ul\u003e\n \u003c\/div\u003e\n \u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003csection class=\"highlight-box\"\u003e\n \u003cdiv class=\"highlight-icon\"\u003e\n \u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n \u003ch3\u003eBiosimilar Supplier Dynamics: A Balancing Act\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"highlight-content\"\u003e\n \u003cp\u003eCoherus Biosciences faces moderate supplier bargaining power due to its use of multiple manufacturers. Standardization in biosimilar production enables supplier switching. Long-term contracts and market competition further limit suppliers' leverage.\u003c\/p\u003e\n \u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n \u003cthead\u003e\n \u003ctr\u003e\n \u003cth\u003eAspect\u003c\/th\u003e\n \u003cth\u003eDetails\u003c\/th\u003e\n \u003cth\u003eImpact\u003c\/th\u003e\n \u003c\/tr\u003e\n \u003c\/thead\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd\u003eSupplier Base\u003c\/td\u003e\n \u003ctd\u003eMultiple manufacturers, some components potentially limited.\u003c\/td\u003e\n \u003ctd\u003eModerate bargaining power.\u003c\/td\u003e\n \u003c\/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003eManufacturing\u003c\/td\u003e\n \u003ctd\u003eStandardized processes; potential for insourcing.\u003c\/td\u003e\n \u003ctd\u003eFlexibility, cost control.\u003c\/td\u003e\n \u003c\/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003eMarket Dynamics\u003c\/td\u003e\n \u003ctd\u003eGrowing biosimilar market (billions by 2028).\u003c\/td\u003e\n \u003ctd\u003eIntensified supplier competition.\u003c\/td\u003e\n \u003c\/tr\u003e\n \u003c\/tbody\u003e\n \u003c\/table\u003e\n \u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n \u003cdiv class=\"text-section text-2_new_design\"\u003e\n \u003cdiv class=\"frst_big_letter_heading\"\u003e\n \u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n \u003csection class=\"sub-highlight-box\"\u003e\n \u003cdiv class=\"sub-highlight-icon\"\u003e\n \u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n \u003ch3\u003ePrice Sensitivity of Buyers\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"sub-highlight-content\"\u003e\n \u003cp\u003eBuyers of Coherus' biosimilars, such as healthcare providers, are highly price-sensitive. This is because biosimilars are designed to be cheaper alternatives to branded biologics. In 2024, the average price discount for biosimilars compared to their reference biologics was around 30-40%. This price sensitivity gives buyers considerable power.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n \u003csection class=\"sub-highlight-box\"\u003e\n \u003cdiv class=\"sub-highlight-icon\"\u003e\n \u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n \u003ch3\u003eConcentrated Customer Base\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"sub-highlight-content\"\u003e\n \u003cp\u003eCoherus Biosciences faces strong buyer power due to a concentrated customer base. A few large entities, like PBMs and insurers, account for a significant revenue share. This concentration gives these customers leverage to demand lower prices. For example, in 2024, a few PBMs controlled a substantial portion of prescription drug sales, increasing their negotiation power.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"image-section image-2_new_design\"\u003e\n \u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003csection class=\"highlight-box\"\u003e\n \u003cdiv class=\"highlight-icon\"\u003e\n \u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n \u003ch3\u003eFormulary Placement Influence\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"highlight-content\"\u003e\n \u003cp\u003eCoherus Biosciences faces customer bargaining power through formulary placement influence. Pharmacy benefit managers (PBMs) and insurers control drug access, impacting biosimilar adoption. These entities negotiate prices, influencing Coherus's revenue. In 2024, PBMs managed over 70% of U.S. prescriptions, highlighting their substantial leverage. \u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n \u003cdiv class=\"product-orange-section\"\u003e\n \u003cdiv class=\"product-box-orange-section4\"\u003e\n \u003cdiv class=\"title-row-orange-section\"\u003e\n \u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n \u003ch3\u003ePhysician Prescribing Preferences\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n \u003cp\u003ePhysician prescribing preferences significantly impact Coherus Biosciences. Doctors' treatment choices influence market share, with brand loyalty potentially outweighing lower prices. Biosimilar adoption is increasing, gradually altering this power dynamic. Coherus must navigate these preferences to succeed. \u003c\/p\u003e\n \u003cul class=\"lst_crct\"\u003e\n \u003cli\u003e\u003cstrong\u003eBiosimilars represent 25% of the US market share in 2024.\u003c\/strong\u003e\u003c\/li\u003e\n \u003cli\u003e\u003cstrong\u003ePhysician hesitancy towards biosimilars is decreasing.\u003c\/strong\u003e\u003c\/li\u003e\n \u003cli\u003e\u003cstrong\u003eCoherus's revenue in 2023 was $481 million.\u003c\/strong\u003e\u003c\/li\u003e\n \u003cli\u003e\u003cstrong\u003eThe market for biosimilars is expected to reach $40 billion by 2027.\u003c\/strong\u003e\u003c\/li\u003e\n \u003c\/ul\u003e\n \u003c\/div\u003e\n \u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"product-box-orange-section4\"\u003e\n \u003cdiv class=\"title-row-orange-section\"\u003e\n \u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n \u003ch3\u003ePatient Choice and Advocacy\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n \u003cp\u003ePatient choice and advocacy play a role, though less directly than payers. Patients sometimes choose treatment options, influencing decisions. Advocacy groups can also shape prescribing practices. This indirect influence still affects customer bargaining power.\u003c\/p\u003e\n \u003cul class=\"lst_crct\"\u003e\n \u003cli\u003e\u003cstrong\u003ePatient advocacy spending in the US reached $2.2 billion in 2023.\u003c\/strong\u003e\u003c\/li\u003e\n \u003cli\u003e\u003cstrong\u003eApproximately 70% of US patients seek online information before medical appointments.\u003c\/strong\u003e\u003c\/li\u003e\n \u003cli\u003e\u003cstrong\u003ePatient choice significantly affects market share in certain therapeutic areas.\u003c\/strong\u003e\u003c\/li\u003e\n \u003c\/ul\u003e\n \u003c\/div\u003e\n \u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003csection class=\"highlight-box\"\u003e\n \u003cdiv class=\"highlight-icon\"\u003e\n \u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n \u003ch3\u003eCoherus's Customer Dynamics: A Buyer's Market\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"highlight-content\"\u003e\n \u003cp\u003eCustomers significantly impact Coherus. Price sensitivity, especially due to biosimilars' nature, gives buyers leverage. Concentrated customer base, like PBMs and insurers, also strengthens buyer power.\u003c\/p\u003e\n \u003cp\u003eFormulary control by PBMs influences Coherus's revenue; PBMs managed over 70% of US prescriptions in 2024. Physician prescribing preferences also play a role, though adoption is increasing.\u003c\/p\u003e\n \u003cp\u003ePatient choice and advocacy indirectly affect bargaining power, with patient advocacy spending in the US reaching $2.2 billion in 2023.\u003c\/p\u003e\n \u003ctable class=\"tbl_prdct orange_head blur_tbl\"\u003e\n \u003cthead\u003e\n \u003ctr\u003e\n \u003cth\u003eFactor\u003c\/th\u003e\n \u003cth\u003eImpact\u003c\/th\u003e\n \u003cth\u003eData (2024)\u003c\/th\u003e\n \u003c\/tr\u003e\n \u003c\/thead\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd\u003ePrice Sensitivity\u003c\/td\u003e\n \u003ctd\u003eHigh\u003c\/td\u003e\n \u003ctd\u003eBiosimilar discounts: 30-40%\u003c\/td\u003e\n \u003c\/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003eCustomer Concentration\u003c\/td\u003e\n \u003ctd\u003eHigh\u003c\/td\u003e\n \u003ctd\u003ePBMs control major sales\u003c\/td\u003e\n \u003c\/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003eFormulary Control\u003c\/td\u003e\n \u003ctd\u003eSignificant\u003c\/td\u003e\n \u003ctd\u003ePBMs manage \u0026gt;70% Rx\u003c\/td\u003e\n \u003c\/tr\u003e\n \u003c\/tbody\u003e\n \u003c\/table\u003e\n \u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n \u003cdiv class=\"text-section text-1_new_design\"\u003e\n \u003cdiv class=\"frst_big_letter_heading\"\u003e\n \u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eivalry Among Competitors\u003c\/span\u003e\n\u003c\/h2\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n \u003csection class=\"sub-highlight-box\"\u003e\n \u003cdiv class=\"sub-highlight-icon\"\u003e\n \u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Chart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n \u003ch3\u003eNumerous Competitors\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"sub-highlight-content\"\u003e\n \u003cp\u003eThe biosimilar and oncology markets are fiercely competitive. Coherus faces rivals like Amgen and Pfizer. This rivalry pressures Coherus to stand out. In 2024, the global oncology market was valued at over $200 billion, showcasing the intense competition for market share.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n \u003csection class=\"sub-highlight-box\"\u003e\n \u003cdiv class=\"sub-highlight-icon\"\u003e\n \u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Chart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n \u003ch3\u003ePricing Pressure\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"sub-highlight-content\"\u003e\n \u003cp\u003ePricing pressure is a significant factor in the biosimilar market, directly impacting Coherus Biosciences. The company faces this pressure as its products compete with lower-cost alternatives. Multiple biosimilars for the same reference product intensify this pressure, often leading to price declines. In 2024, the biosimilar market saw average price reductions of 10-15% due to intense competition.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"image-section image-1_new_design\"\u003e\n \u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Image.svg\" alt=\"Explore a Preview\"\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003csection class=\"highlight-box\"\u003e\n \u003cdiv class=\"highlight-icon\"\u003e\n \u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Chart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n \u003ch3\u003eFocus on Innovation\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"highlight-content\"\u003e\n \u003cp\u003eCoherus's move into innovative oncology changes the competitive landscape. Success hinges on clinical outcomes and novel approaches. In 2024, the oncology market was valued at over $200 billion. Strong R\u0026amp;D is crucial for competitive advantage.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n \u003cdiv class=\"product-green-section\"\u003e\n \u003cdiv class=\"product-box-green-section4\"\u003e\n \u003cdiv class=\"title-row-green-section\"\u003e\n \u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Chart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n \u003ch3\u003eStrategic Divestitures\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"content-row-green-section blur_box\"\u003e\n \u003cp\u003eCoherus Biosciences has strategically divested some of its biosimilar assets, which indicates a shift in focus. This move might lower competitive intensity in specific biosimilar areas. However, it also places Coherus in the highly competitive oncology market. The company aims to strengthen its position in this challenging sector. This strategic adjustment impacts its competitive dynamics.\u003c\/p\u003e\n \u003cul class=\"lst_crct\"\u003e\n \u003cli\u003e\u003cstrong\u003eCoherus divested Cimerli in 2024, impacting its biosimilar portfolio.\u003c\/strong\u003e\u003c\/li\u003e\n \u003cli\u003e\u003cstrong\u003eThe oncology market is projected to reach $440 billion by 2027, making it highly competitive.\u003c\/strong\u003e\u003c\/li\u003e\n \u003cli\u003e\u003cstrong\u003eStrategic shifts like divestitures aim to improve financial health and market focus.\u003c\/strong\u003e\u003c\/li\u003e\n \u003c\/ul\u003e\n \u003c\/div\u003e\n \u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"product-box-green-section4\"\u003e\n \u003cdiv class=\"title-row-green-section\"\u003e\n \u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Chart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n \u003ch3\u003eMarket Share Concentration\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"content-row-green-section blur_box\"\u003e\n \u003cp\u003eCompetitive rivalry in the biosimilars market, including Coherus Biosciences, is intense. Market share concentration varies; some segments are dominated by a few key players. This concentration fuels aggressive competition, affecting profitability. In 2024, the biosimilars market is estimated at $40 billion, growing significantly.\u003c\/p\u003e\n \u003cul class=\"lst_crct\"\u003e\n \u003cli\u003e\u003cstrong\u003eTop companies include Pfizer and Amgen.\u003c\/strong\u003e\u003c\/li\u003e\n \u003cli\u003e\u003cstrong\u003eCompetition drives down prices.\u003c\/strong\u003e\u003c\/li\u003e\n \u003cli\u003e\u003cstrong\u003eCoherus faces this rivalry.\u003c\/strong\u003e\u003c\/li\u003e\n \u003cli\u003e\u003cstrong\u003eMarket growth offers opportunities.\u003c\/strong\u003e\u003c\/li\u003e\n \u003c\/ul\u003e\n \u003c\/div\u003e\n \u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003csection class=\"highlight-box\"\u003e\n \u003cdiv class=\"highlight-icon\"\u003e\n \u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Chart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n \u003ch3\u003eBiosimilar \u0026amp; Oncology Market Clash\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"highlight-content\"\u003e\n \u003cp\u003eCoherus battles strong rivalry in biosimilars and oncology. Competitors like Amgen and Pfizer push for market share. Price pressure and diverse biosimilars intensify challenges. The oncology market, valued over $200B in 2024, fuels competition.\u003c\/p\u003e\n \u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n \u003cthead\u003e\n \u003ctr\u003e\n \u003cth\u003eAspect\u003c\/th\u003e\n \u003cth\u003eDetails\u003c\/th\u003e\n \u003cth\u003eImpact\u003c\/th\u003e\n \u003c\/tr\u003e\n \u003c\/thead\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd\u003eMarket Size (2024)\u003c\/td\u003e\n \u003ctd\u003eOncology: Over $200B, Biosimilars: $40B\u003c\/td\u003e\n \u003ctd\u003eHigh competition\u003c\/td\u003e\n \u003c\/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003eKey Players\u003c\/td\u003e\n \u003ctd\u003eAmgen, Pfizer, Coherus\u003c\/td\u003e\n \u003ctd\u003eInfluences market dynamics\u003c\/td\u003e\n \u003c\/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003ePrice Pressure\u003c\/td\u003e\n \u003ctd\u003eBiosimilars saw 10-15% price drops in 2024\u003c\/td\u003e\n \u003ctd\u003eAffects profitability\u003c\/td\u003e\n \u003c\/tr\u003e\n \u003c\/tbody\u003e\n \u003c\/table\u003e\n \u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n \u003cdiv class=\"text-section text-2_new_design\"\u003e\n \u003cdiv class=\"frst_big_letter_heading\"\u003e\n \u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eSubstitutes Threaten\u003c\/span\u003e\n\u003c\/h2\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n \u003csection class=\"sub-highlight-box\"\u003e\n \u003cdiv class=\"sub-highlight-icon\"\u003e\n \u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Substitutes-Arrows-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n \u003ch3\u003eAlternative Biosimilars\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"sub-highlight-content\"\u003e\n \u003cp\u003eThe primary substitutes for Coherus' biosimilars are rival biosimilars designed to mirror the same reference product. The intensity of this threat rises with the number of available biosimilars, as customers can readily switch based on pricing or specific advantages. In 2024, the biosimilar market saw increased competition, with multiple companies vying for market share, impacting Coherus' pricing strategies. For example, the average price of biosimilars decreased by 10-15% due to this competition. \u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n \u003csection class=\"sub-highlight-box\"\u003e\n \u003cdiv class=\"sub-highlight-icon\"\u003e\n \u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Substitutes-Arrows-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n \u003ch3\u003eBranded Biologics\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"sub-highlight-content\"\u003e\n \u003cp\u003eBranded biologics pose a threat to Coherus Biosciences. Despite biosimilars' similarity, some prefer the original. This preference limits Coherus's market share. In 2024, branded biologics held a significant market share. This highlights the ongoing challenge for biosimilar adoption.\n \u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"image-section image-2_new_design\"\u003e\n \u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Substitutes-Image.svg\" alt=\"Explore a Preview\"\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003csection class=\"highlight-box\"\u003e\n \u003cdiv class=\"highlight-icon\"\u003e\n \u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Substitutes-Arrows-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n \u003ch3\u003eOther Treatment Modalities\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"highlight-content\"\u003e\n \u003cp\u003eCoherus Biosciences faces the threat of substitute treatments, particularly in oncology. Small molecule drugs, radiation, or surgery can replace biologics and biosimilars. For example, in 2024, the global oncology market reached approximately $200 billion. The availability of these alternatives impacts Coherus' market share and pricing strategies.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n \u003cdiv class=\"product-orange-section\"\u003e\n \u003cdiv class=\"product-box-orange-section4\"\u003e\n \u003cdiv class=\"title-row-orange-section\"\u003e\n \u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Substitutes-Arrows-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n \u003ch3\u003eEmerging Therapies\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n \u003cp\u003eThe biopharmaceutical sector is dynamic, with innovative therapies continuously appearing. These new treatments could substitute current biologics and biosimilars, presenting a long-term substitution risk for Coherus Biosciences. For instance, gene therapies and mRNA-based medicines are advancing, potentially affecting the market position of existing drugs. The rise of these alternatives necessitates Coherus to stay adaptable.\u003c\/p\u003e\n \u003cul class=\"lst_crct\"\u003e\n \u003cli\u003e\u003cstrong\u003eGene therapies have the potential to offer one-time cures, reducing the need for ongoing treatments.\u003c\/strong\u003e\u003c\/li\u003e\n \u003cli\u003e\u003cstrong\u003emRNA technology is rapidly expanding into various disease areas, providing new treatment options.\u003c\/strong\u003e\u003c\/li\u003e\n \u003cli\u003e\u003cstrong\u003eIn 2024, the FDA approved a record number of novel therapies, many of which could be substitutes.\u003c\/strong\u003e\u003c\/li\u003e\n \u003cli\u003e\u003cstrong\u003eCoherus must invest in R\u0026amp;D to stay competitive against these emerging substitutes.\u003c\/strong\u003e\u003c\/li\u003e\n \u003c\/ul\u003e\n \u003c\/div\u003e\n \u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"product-box-orange-section4\"\u003e\n \u003cdiv class=\"title-row-orange-section\"\u003e\n \u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Substitutes-Arrows-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n \u003ch3\u003ePreventative Measures\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n \u003cp\u003eThe threat of substitutes for Coherus Biosciences is present in the form of preventative measures or lifestyle changes. These alternatives, though indirect, can lessen the demand for their biologic therapies. For example, adopting healthier habits might reduce the need for certain treatments. This dynamic underscores the importance of understanding how broader health trends influence the market. In 2024, the global biosimilars market, where Coherus operates, was valued at approximately $25 billion, and is projected to reach $70 billion by 2030.\u003c\/p\u003e\n \u003cul class=\"lst_crct\"\u003e\n \u003cli\u003e\u003cstrong\u003ePreventative strategies and lifestyle changes can reduce the need for Coherus's products.\u003c\/strong\u003e\u003c\/li\u003e\n \u003cli\u003e\u003cstrong\u003eThe biosimilars market was valued at $25 billion in 2024.\u003c\/strong\u003e\u003c\/li\u003e\n \u003cli\u003e\u003cstrong\u003eThe biosimilars market is projected to reach $70 billion by 2030.\u003c\/strong\u003e\u003c\/li\u003e\n \u003cli\u003e\u003cstrong\u003eMarket dynamics are influenced by overall health trends.\u003c\/strong\u003e\u003c\/li\u003e\n \u003c\/ul\u003e\n \u003c\/div\u003e\n \u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003csection class=\"highlight-box\"\u003e\n \u003cdiv class=\"highlight-icon\"\u003e\n \u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Substitutes-Arrows-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n \u003ch3\u003eCoherus: Facing Market Challenges and Threats\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"highlight-content\"\u003e\n \u003cp\u003eCoherus faces substitution risks from rival biosimilars and branded biologics, affecting pricing and market share. The oncology sector sees competition from small molecule drugs and other treatments, potentially impacting Coherus' sales. Emerging therapies, like gene therapies, pose long-term threats requiring adaptability and investment in research and development.\u003c\/p\u003e\n \u003ctable class=\"tbl_prdct orange_head blur_tbl\"\u003e\n \u003cthead\u003e\n \u003ctr\u003e\n \u003cth\u003eSubstitute Type\u003c\/th\u003e\n \u003cth\u003eImpact\u003c\/th\u003e\n \u003cth\u003e2024 Data\u003c\/th\u003e\n \u003c\/tr\u003e\n \u003c\/thead\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd\u003eRival Biosimilars\u003c\/td\u003e\n \u003ctd\u003ePrice pressure, market share loss\u003c\/td\u003e\n \u003ctd\u003eAverage biosimilar price decrease: 10-15%\u003c\/td\u003e\n \u003c\/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003eBranded Biologics\u003c\/td\u003e\n \u003ctd\u003eLimit market share growth\u003c\/td\u003e\n \u003ctd\u003eSignificant market share held by original products.\u003c\/td\u003e\n \u003c\/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003eAlternative Therapies\u003c\/td\u003e\n \u003ctd\u003eReduced demand for biosimilars\u003c\/td\u003e\n \u003ctd\u003eOncology market ≈ $200 billion in 2024\u003c\/td\u003e\n \u003c\/tr\u003e\n \u003c\/tbody\u003e\n \u003c\/table\u003e\n \u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n \u003cdiv class=\"text-section text-1_new_design\"\u003e\n \u003cdiv class=\"frst_big_letter_heading\"\u003e\n \u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003entrants Threaten\u003c\/span\u003e\n\u003c\/h2\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n \u003csection class=\"sub-highlight-box\"\u003e\n \u003cdiv class=\"sub-highlight-icon\"\u003e\n \u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Lamp-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n \u003ch3\u003eHigh Regulatory Hurdles\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"sub-highlight-content\"\u003e\n \u003cp\u003eCoherus Biosciences faces significant barriers due to strict regulations. The biopharmaceutical sector demands costly clinical trials and adherence to manufacturing standards. For example, in 2024, the FDA's approval process for biosimilars can take several years and millions of dollars. These high costs and regulatory complexities deter new entrants.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n \u003csection class=\"sub-highlight-box\"\u003e\n \u003cdiv class=\"sub-highlight-icon\"\u003e\n \u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Lamp-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n \u003ch3\u003eSignificant Capital Investment\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"sub-highlight-content\"\u003e\n \u003cp\u003eCoherus Biosciences faces a significant barrier from new entrants due to the high capital investment needed for biosimilar and novel therapy development. R\u0026amp;D, manufacturing, and marketing demand substantial financial resources. For example, in 2024, the average cost to bring a new drug to market was approximately $2.6 billion. This financial hurdle limits the number of potential competitors. \u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"image-section image-1_new_design\"\u003e\n \u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Image.svg\" alt=\"Explore a Preview\"\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003csection class=\"highlight-box\"\u003e\n \u003cdiv class=\"highlight-icon\"\u003e\n \u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Lamp-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n \u003ch3\u003eEstablished Players' Dominance\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"highlight-content\"\u003e\n \u003cp\u003eThe biopharmaceutical market is heavily influenced by well-established entities, creating a formidable barrier for newcomers. These industry giants possess extensive financial backing, crucial for navigating the complex regulatory landscape and funding extensive research and development. For instance, in 2024, companies like Johnson \u0026amp; Johnson and Roche continued to lead in revenue, showcasing their enduring market power. Their established relationships with healthcare providers and payers create a significant hurdle for new entrants.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n \u003cdiv class=\"product-green-section\"\u003e\n \u003cdiv class=\"product-box-green-section4\"\u003e\n \u003cdiv class=\"title-row-green-section\"\u003e\n \u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Lamp-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n \u003ch3\u003ePatent Protection\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"content-row-green-section blur_box\"\u003e\n \u003cp\u003ePatent protection poses a notable threat to new entrants in the biosimilar market. Biosimilars aim to bypass patents on original biologics, but entrants must still maneuver through intricate patent systems. This necessity can create significant barriers to market entry. In 2024, the average cost to defend a patent infringement case in the U.S. reached $3.5 million. \u003c\/p\u003e\n \u003cul class=\"lst_crct\"\u003e\n \u003cli\u003e\u003cstrong\u003eNavigating patent landscapes is costly and time-consuming.\u003c\/strong\u003e\u003c\/li\u003e\n \u003cli\u003e\u003cstrong\u003eInfringement litigation can be extremely expensive.\u003c\/strong\u003e\u003c\/li\u003e\n \u003cli\u003e\u003cstrong\u003ePatent challenges can delay or prevent market entry.\u003c\/strong\u003e\u003c\/li\u003e\n \u003cli\u003e\u003cstrong\u003eSuccessful biosimilars often require multiple patent workarounds.\u003c\/strong\u003e\u003c\/li\u003e\n \u003c\/ul\u003e\n \u003c\/div\u003e\n \u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"product-box-green-section4\"\u003e\n \u003cdiv class=\"title-row-green-section\"\u003e\n \u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Lamp-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n \u003ch3\u003eBrand Recognition and Trust\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"content-row-green-section blur_box\"\u003e\n \u003cp\u003eBuilding brand recognition and trust with physicians and patients is crucial for success in the pharmaceutical industry. New entrants often face significant challenges in this area. Established companies, like Coherus Biosciences, benefit from a long history of providing safe and effective therapies, which fosters loyalty. This advantage makes it difficult for new competitors to quickly gain market share.\u003c\/p\u003e\n \u003cul class=\"lst_crct\"\u003e\n \u003cli\u003e\u003cstrong\u003eCoherus Biosciences, as of 2024, has established relationships with healthcare providers.\u003c\/strong\u003e\u003c\/li\u003e\n \u003cli\u003e\u003cstrong\u003eNew entrants need time and resources to build similar trust levels.\u003c\/strong\u003e\u003c\/li\u003e\n \u003cli\u003e\u003cstrong\u003ePatient and physician confidence significantly impacts product adoption rates.\u003c\/strong\u003e\u003c\/li\u003e\n \u003cli\u003e\u003cstrong\u003eEstablished brands often have a competitive edge in the market.\u003c\/strong\u003e\u003c\/li\u003e\n \u003c\/ul\u003e\n \u003c\/div\u003e\n \u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003csection class=\"highlight-box\"\u003e\n \u003cdiv class=\"highlight-icon\"\u003e\n \u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Lamp-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n \u003ch3\u003eCoherus' Edge: Barriers to Entry\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"highlight-content\"\u003e\n \u003cp\u003eCoherus Biosciences benefits from regulatory hurdles and high capital costs, deterring new biosimilar competitors. Established companies have advantages in the pharmaceutical market, with brand trust being a key differentiator.\u003c\/p\u003e\n \u003cp\u003e Patent protection and the cost of litigation are significant entry barriers, potentially delaying or preventing newcomers from entering the market.\u003c\/p\u003e\n \u003cp\u003eBuilding brand recognition and physician trust is difficult for new entrants, favoring established companies like Coherus Biosciences. \u003c\/p\u003e\n \u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n \u003cthead\u003e\n \u003ctr\u003e\n \u003cth\u003eBarrier\u003c\/th\u003e\n \u003cth\u003eImpact\u003c\/th\u003e\n \u003cth\u003eExample (2024)\u003c\/th\u003e\n \u003c\/tr\u003e\n \u003c\/thead\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd\u003eRegulatory Compliance\u003c\/td\u003e\n \u003ctd\u003eDelays, Costs\u003c\/td\u003e\n \u003ctd\u003eFDA approval takes years, millions of dollars\u003c\/td\u003e\n \u003c\/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003eCapital Investment\u003c\/td\u003e\n \u003ctd\u003eHigh Entry Cost\u003c\/td\u003e\n \u003ctd\u003eAvg. drug development cost: $2.6B\u003c\/td\u003e\n \u003c\/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003ePatent Challenges\u003c\/td\u003e\n \u003ctd\u003eLegal Risks\u003c\/td\u003e\n \u003ctd\u003ePatent case cost: $3.5M\u003c\/td\u003e\n \u003c\/tr\u003e\n \u003c\/tbody\u003e\n \u003c\/table\u003e\n \u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n \u003cdiv class=\"text-section text-2_new_design\"\u003e\n \u003ch2\u003ePorter's Five Forces Analysis \u003cspan style=\"color: #FB9C46;\"\u003eData Sources\u003c\/span\u003e\n\u003c\/h2\u003e\n \u003cp\u003eThis analysis leverages financial reports, industry studies, competitor analysis, and market data from reputable sources for comprehensive insights. \u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"image-section image-2_new_design\"\u003e\n \u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Data-Sources.svg\" alt=\"Data Sources\"\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e","brand":"SAE","offers":[{"title":"Default Title","offer_id":55890468667776,"sku":"coherus-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0899\/6510\/1440\/files\/coherus-five-forces-analysis.png?v=1745078013","url":"https:\/\/swotanalysistemplates.com\/products\/coherus-five-forces-analysis","provider":"SWOT Analysis Templates","version":"1.0","type":"link"}